| scholarly article | Q13442814 |
| P50 | author | Kornelis S M van der Geest | Q85210399 |
| Andor W J M Glaudemans | Q91190461 | ||
| P2093 | author name string | Elisabeth Brouwer | |
| Suzanne Arends | |||
| Karel-Jan D F Lensen | |||
| Riemer H J A Slart | |||
| Menno D Stellingwerff | |||
| Abraham Rutgers | |||
| P2860 | cites work | Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography | Q26865857 |
| Imaging of large vessel vasculitis with (18)FDG PET: illusion or reality? A critical review of the literature data | Q30804314 | ||
| Disease pattern in cranial and large-vessel giant cell arteritis | Q33534693 | ||
| Diagnostic performance of ¹⁸F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis | Q33895383 | ||
| Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients | Q33993390 | ||
| The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis | Q34227003 | ||
| 18F-fluorodeoxyglucose positron emission tomography in elderly patients with an elevated erythrocyte sedimentation rate of unknown origin | Q34634391 | ||
| Are polymyalgia rheumatica and giant cell arteritis the same disease? | Q35744074 | ||
| 18F-Fludeoxyglucose PET/CT in the evaluation of large-vessel vasculitis: diagnostic performance and correlation with clinical and laboratory parameters | Q36326221 | ||
| Clinical feasibility of molecular imaging of plaque inflammation in atherosclerosis | Q37395235 | ||
| FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. | Q37469186 | ||
| Recent advances in diagnostic strategies for giant cell arteritis | Q37972084 | ||
| Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment | Q37979583 | ||
| 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease | Q39946694 | ||
| Patterns of extracranial involvement in newly diagnosed giant cell arteritis assessed by physical examination, colour coded duplex sonography and FDG-PET. | Q40322778 | ||
| Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for therapy evaluation of patients with large-vessel vasculitis. | Q40359743 | ||
| Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. | Q40562002 | ||
| Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio | Q43936771 | ||
| Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study | Q44951982 | ||
| The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease | Q45300713 | ||
| Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study | Q48952305 | ||
| The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. | Q50654581 | ||
| Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. | Q53073312 | ||
| Towards an optimal semiquantitative approach in giant cell arteritis: an (18)F-FDG PET/CT case-control study. | Q53096424 | ||
| The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. | Q53142320 | ||
| [Imaging diagnostics of large vessel vasculitis]. | Q53277825 | ||
| Direct proinflammatory effect of C-reactive protein on human endothelial cells | Q73134567 | ||
| New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography | Q77889493 | ||
| Giant cell arteritis: heterogeneity in clinical presentation and imaging results | Q81666296 | ||
| Polymyalgia rheumatica and giant-cell arteritis | Q81668995 | ||
| 18F-FDG PET as a diagnostic procedure in large vessel vasculitis—a controlled, blinded re-examination of routine PET scans | Q82037506 | ||
| P433 | issue | 37 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | giant cell arteritis | Q707816 |
| Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography | Q130273251 | ||
| P304 | page(s) | e1542 | |
| P577 | publication date | 2015-09-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Different Scoring Methods of FDG PET/CT in Giant Cell Arteritis: Need for Standardization | |
| P478 | volume | 94 |
| Q90911186 | Clinical Factors Associated with Time-Specific Distribution of 18F-Fluorodeoxyglucose in Large-Vessel Vasculitis |
| Q38601091 | Effect of CRP value on (18)F-FDG PET vascular positivity in Takayasu arteritis: a systematic review and per-patient based meta-analysis |
| Q90402486 | European Headache Federation recommendations for neurologists managing giant cell arteritis |
| Q38950827 | F-18 FDG PET/CT imaging of cardiac and vascular inflammation and infection |
| Q54238129 | FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. |
| Q37364920 | Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: A single-center, retrospective study of 70 patients. |
| Q52578815 | Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. |
| Q47617064 | [18F]FDG positron emission tomography in patients presenting with suspicion of giant cell arteritis-lessons from a vasculitis clinic. |
Search more.